| 4017 | Humans |
| 3962 | Animals |
| 2102 | Male |
| 1607 | Female |
| 1410 | Mice |
| 1037 | Rats |
| 1012 | Models, Biological |
| 769 | Antineoplastic Agents |
| 687 | Signal Transduction |
| 654 | Tumor Necrosis Factor-alpha |
| 627 | Adult |
| 591 | Hypoglycemic Agents |
| 589 | Middle Aged |
| 585 | Apoptosis |
| 577 | Insulin |
| 528 | Cytokines |
| 511 | Disease Models, Animal |
| 511 | Cell Line, Tumor |
| 501 | Anti-Bacterial Agents |
| 491 | Cells, Cultured |
| 484 | Dose-Response Relationship, Drug |
| 459 | Anti-Inflammatory Agents |
| 446 | Time Factors |
| 408 | Cell Proliferation |
| 395 | Mice, Inbred C57BL |
| 393 | Rats, Sprague-Dawley |
| 377 | Peptides |
| 374 | Aged |
| 372 | Biological Transport |
| 354 | Immunosuppressive Agents |
| 353 | Cell Line |
| 352 | Cell Survival |
| 339 | Treatment Outcome |
| 339 | Blood Glucose |
| 331 | Rats, Wistar |
| 299 | Inflammation |
| 297 | Biological Products |
| 290 | Gene Expression Regulation |
| 282 | Amino Acid Sequence |
| 275 | Neoplasms |
| 271 | Mice, Inbred BALB C |
| 269 | RNA, Messenger |
| 268 | Recombinant Proteins |
| 267 | Neuroprotective Agents |
| 266 | Molecular Sequence Data |
| 256 | Biological Availability |
| 248 | Phosphorylation |
| 242 | Oxidative Stress |
| 242 | Antioxidants |
| 237 | Antibodies, Monoclonal |
| 233 | Biomarkers |
| 218 | Antiviral Agents |
| 217 | Case-Control Studies |
| 212 | Plant Extracts |
| 211 | NF-kappa B |
| 211 | Antirheumatic Agents |
| 206 | Diabetes Mellitus, Type 2 |
| 204 | Peptide Fragments |
| 204 | Microbial Sensitivity Tests |
| 198 | Liver |
| 195 | Cyclosporine |
| 187 | Anti-Inflammatory Agents, Non-Steroidal |
| 184 | Interleukin-6 |
| 184 | Glutathione |
| 182 | Arthritis, Rheumatoid |
| 179 | In Vitro Techniques |
| 175 | Tumor Cells, Cultured |
| 172 | Enzyme Inhibitors |
| 171 | Lipopolysaccharides |
| 171 | Gene Expression |
| 171 | Antifungal Agents |
| 168 | Blotting, Western |
| 167 | Administration, Oral |
| 166 | Adolescent |
| 162 | Drug Delivery Systems |
| 160 | Kinetics |
| 158 | Drug Therapy, Combination |
| 157 | Bacterial Proteins |
| 156 | Nitric Oxide |
| 155 | Structure-Activity Relationship |
| 155 | Neurons |
| 155 | Antibodies, Monoclonal, Humanized |
| 151 | Glucose |
| 147 | Peptides, Cyclic |
| 147 | Oligopeptides |
| 145 | Vascular Endothelial Growth Factor A |
| 145 | Brain |
| 144 | Young Adult |
| 143 | Macrophages |
| 142 | Reactive Oxygen Species |
| 142 | Protective Agents |
| 141 | Plant Diseases |
| 140 | Gene Expression Regulation, Neoplastic |
| 138 | Calcium |
| 137 | Biological Control Agents |
| 136 | Diabetes Mellitus, Type 1 |
| 136 | Biological Assay |
| 135 | Breast Neoplasms |
| 135 | Anti-Infective Agents |
| 134 | Mutation |
| 133 | Caspase 3 |
| 132 | Cell Movement |
| 131 | Up-Regulation |
| 131 | Inflammation Mediators |
| 130 | Mice, Nude |
| 129 | Transfection |
| 128 | Protein Binding |
| 128 | Pest Control, Biological |
| 128 | Cell Division |
| 127 | Interferon-gamma |
| 127 | Drug Carriers |
| 125 | Down-Regulation |
| 121 | Risk Factors |
| 121 | Mice, Knockout |
| 121 | Enzyme Activation |
| 120 | Neurotransmitter Agents |
| 120 | Antimicrobial Cationic Peptides |
| 119 | Proto-Oncogene Proteins c-bcl-2 |
| 119 | Endothelium, Vascular |
| 118 | Diabetes Mellitus, Experimental |
| 117 | Neovascularization, Pathologic |
| 115 | Molecular Structure |
| 115 | Lung |
| 113 | Enzyme-Linked Immunosorbent Assay |
| 112 | Etanercept |
| 111 | Escherichia coli |
| 111 | Cell Differentiation |
| 109 | Xenograft Model Antitumor Assays |
| 109 | Drug Design |
| 108 | Insulin Resistance |
| 108 | Child |
| 108 | Cell Membrane |
| 107 | Immunohistochemistry |
| 106 | Infliximab |
| 106 | Immunoglobulin G |
| 104 | Reverse Transcriptase Polymerase Chain Reaction |
| 104 | Clinical Trials as Topic |
| 103 | Obesity |
| 102 | Lipopeptides |
| 102 | Disease Progression |
| 101 | T-Lymphocytes |
| 99 | Rabbits |
| 99 | Drug Administration Schedule |
| 99 | Cell Cycle |
| 99 | Amyloid beta-Peptides |
| 98 | Mice, Transgenic |
| 98 | Computer Simulation |
| 98 | Chromatography, High Pressure Liquid |
| 97 | Vasodilator Agents |
| 97 | Nanoparticles |
| 97 | Mitochondria |
| 97 | Base Sequence |
| 97 | Antineoplastic Agents, Phytogenic |
| 96 | Interleukin-1beta |
| 96 | Drug Evaluation, Preclinical |
| 96 | Cattle |
| 95 | Recombinant Fusion Proteins |
| 95 | Aged, 80 and over |
| 94 | Kidney |
| 94 | Algorithms |
| 93 | Pregnancy |
| 93 | Drug Synergism |
| 93 | Body Weight |
| 93 | Antihypertensive Agents |
| 91 | Prospective Studies |
| 90 | Receptors, Tumor Necrosis Factor |
| 90 | Phytotherapy |
| 90 | Fibroblasts |
| 89 | Blood Pressure |
| 88 | Retrospective Studies |
| 88 | Biological Factors |
| 88 | Bacteria |
| 88 | Alzheimer Disease |
| 87 | Swine |
| 86 | Models, Molecular |
| 86 | Lung Neoplasms |
| 85 | Severity of Illness Index |
| 85 | Proteins |
| 85 | Protein Kinase Inhibitors |
| 85 | Immunologic Factors |
| 85 | Graft Rejection |
| 84 | Vancomycin |
| 84 | Proto-Oncogene Proteins c-akt |
| 84 | Hydrogen-Ion Concentration |
| 84 | Gene Expression Profiling |
| 83 | Transcription Factors |
| 83 | Drug Screening Assays, Antitumor |
| 83 | Angiogenesis Inhibitors |
| 81 | Transforming Growth Factor beta |
| 81 | Hippocampus |
| 81 | Cardiotonic Agents |
| 81 | Anticarcinogenic Agents |
| 80 | Random Allocation |
| 80 | Interferons |
| 80 | Interferon-alpha |
| 80 | Hypertension |
| 80 | Hyperglycemia |
| 80 | Adalimumab |
| 79 | Polyethylene Glycols |
| 79 | Peptide Hydrolases |
| 78 | Reproducibility of Results |
| 77 | Bacillus |
| 76 | Randomized Controlled Trials as Topic |
| 76 | Mitogen-Activated Protein Kinases |
| 76 | DNA |
| 75 | Phenotype |
| 75 | Neoplasm Invasiveness |
| 75 | HeLa Cells |
| 75 | Area Under Curve |
| 74 | Drug Resistance, Neoplasm |
| 74 | Cyclic AMP |
| 74 | Analysis of Variance |
| 73 | Myocardium |
| 73 | Ligands |
| 73 | Intercellular Signaling Peptides and Proteins |
| 73 | Flow Cytometry |
| 73 | Cloning, Molecular |
| 73 | Cell Death |
| 72 | Superoxide Dismutase |
| 72 | Protein-Serine-Threonine Kinases |
| 72 | Neutrophils |
| 72 | Methotrexate |
| 72 | Larva |
| 72 | Biofilms |
| 71 | Particle Size |
| 71 | Biological Transport, Active |
| 71 | Binding Sites |
| 70 | Psoriasis |
| 70 | Molecular Targeted Therapy |
| 69 | bcl-2-Associated X Protein |
| 69 | Intracellular Signaling Peptides and Proteins |
| 69 | Follow-Up Studies |
| 69 | DNA-Binding Proteins |
| 69 | Carrier Proteins |
| 68 | Tissue Distribution |
| 68 | RNA, Small Interfering |
| 68 | Neoplasm Proteins |
| 68 | Fungi |
| 68 | Endothelial Cells |
| 68 | Caspases |
| 67 | Prognosis |
| 67 | Neuropeptides |
| 67 | Angiotensin II |
| 66 | Transcription, Genetic |
| 66 | Promoter Regions, Genetic |
| 66 | Nerve Tissue Proteins |
| 66 | Membrane Proteins |
| 65 | Staphylococcus aureus |
| 65 | Neoplasm Metastasis |
| 65 | Diabetes Mellitus |
| 64 | Skin |
| 64 | MAP Kinase Signaling System |
| 64 | Hypoglycemia |
| 64 | Doxorubicin |
| 63 | Lipid Peroxidation |
| 62 | Oxidation-Reduction |
| 62 | Flavonoids |
| 62 | AMP-Activated Protein Kinases |
| 61 | Virus Replication |
| 61 | Sequence Analysis, DNA |
| 61 | Rats, Inbred Strains |
| 61 | Interleukin-1 |
| 61 | Fungal Proteins |
| 61 | Cardiovascular Diseases |
| 60 | Intestinal Mucosa |
| 60 | Glycated Hemoglobin A |
| 60 | Cyclooxygenase 2 |
| 59 | p38 Mitogen-Activated Protein Kinases |
| 59 | Phylogeny |
| 59 | Mass Spectrometry |
| 59 | Interleukin-2 |
| 59 | Insulin Secretion |
| 59 | Epithelial Cells |
| 59 | Dogs |
| 58 | Thiazoles |
| 58 | Prostatic Neoplasms |
| 58 | Predictive Value of Tests |
| 58 | Nitric Oxide Synthase Type II |
| 58 | Nerve Growth Factors |
| 58 | Energy Metabolism |
| 58 | Cell Adhesion |
| 57 | Bacillus subtilis |
| 56 | Immunity, Innate |
| 56 | Homeostasis |
| 56 | DNA Damage |
| 55 | Matrix Metalloproteinase 9 |
| 55 | Lipids |
| 55 | Insect Proteins |
| 55 | Dietary Supplements |
| 55 | Adenosine Triphosphate |
| 54 | Mice, Inbred ICR |
| 54 | Lymphocyte Activation |
| 54 | Kidney Transplantation |
| 54 | Interleukin-10 |
| 54 | Insulin Infusion Systems |
| 54 | Cricetinae |
| 54 | Cisplatin |
| 54 | Chemistry, Pharmaceutical |
| 54 | Biological Therapy |
| 54 | Acetylcholine |
| 53 | Spleen |
| 53 | STAT3 Transcription Factor |
| 53 | Protein Kinase C |
| 53 | Protein Conformation |
| 53 | Neoplasm Transplantation |
| 53 | Inflammatory Bowel Diseases |
| 53 | Cholesterol |
| 53 | Brain-Derived Neurotrophic Factor |
| 53 | Bone Density Conservation Agents |
| 53 | Antibiosis |
| 53 | Adipose Tissue |
| 52 | Vasodilation |
| 52 | Vasoconstrictor Agents |
| 52 | Surface-Active Agents |
| 52 | Polymerase Chain Reaction |
| 52 | Plasmids |
| 52 | Plant Leaves |
| 52 | Insecticides |
| 52 | Heart |
| 52 | HEK293 Cells |
| 52 | Antidepressive Agents |
| 52 | Amino Acids |
| 51 | Survival Analysis |
| 51 | Reperfusion Injury |
| 51 | Real-Time Polymerase Chain Reaction |
| 51 | Glucagon-Like Peptide 1 |
| 51 | Genetic Vectors |
| 51 | Drug Stability |
| 51 | Drug Monitoring |
| 51 | Chronic Disease |
| 51 | Child, Preschool |
| 50 | Tumor Suppressor Protein p53 |
| 50 | Phosphatidylinositol 3-Kinases |
| 50 | Ovalbumin |
| 50 | Myocytes, Cardiac |
| 50 | Injections, Subcutaneous |
| 50 | Indoles |
| 50 | HIV Infections |
| 50 | Drug Interactions |
| 50 | Dinoprostone |
| 50 | Asthma |
| 50 | Animals, Newborn |
| 49 | Pyridines |
| 49 | Polymers |
| 49 | Muscle, Skeletal |
| 49 | Molecular Weight |
| 49 | Metformin |
| 49 | Leukocytes, Mononuclear |
| 49 | Glucocorticoids |
| 49 | Gastrointestinal Agents |
| 49 | Collagen |
| 49 | Behavior, Animal |
| 49 | Adipocytes |
| 48 | Triglycerides |
| 48 | Thiazolidinediones |
| 48 | Solubility |
| 48 | Matrix Metalloproteinase 2 |
| 48 | Estradiol |
| 48 | Drug Resistance, Bacterial |
| 48 | Double-Blind Method |
| 48 | Combined Modality Therapy |
| 48 | Apoptosis Regulatory Proteins |
| 47 | Wound Healing |
| 47 | Temperature |
| 47 | Muscle, Smooth, Vascular |
| 47 | Dexamethasone |
| 47 | Antineoplastic Agents, Hormonal |
| 47 | Aging |
| 46 | Osteoporosis |
| 46 | Interferon Type I |
| 46 | Insulin-Secreting Cells |
| 46 | Chelating Agents |
| 46 | Adrenal Cortex Hormones |
| 45 | Staphylococcal Infections |
| 45 | Protein Structure, Tertiary |
| 45 | Membrane Glycoproteins |
| 45 | Intestinal Absorption |
| 45 | Interleukin-8 |
| 45 | Glucose Tolerance Test |
| 45 | Endotoxins |
| 45 | Brain Ischemia |
| 45 | Antineoplastic Combined Chemotherapy Protocols |
| 44 | Tacrolimus |
| 44 | Risk Assessment |
| 44 | RNA Interference |
| 44 | Monocytes |
| 44 | Malondialdehyde |
| 44 | Liver Neoplasms |
| 44 | Hydrogen Peroxide |
| 44 | Hepatocytes |
| 44 | Hep G2 Cells |
| 44 | Glucose Transporter Type 4 |
| 44 | Genotype |
| 44 | Ethanol |
| 44 | ErbB Receptors |
| 44 | Delayed-Action Preparations |
| 44 | Caco-2 Cells |
| 43 | Pyrimidines |
| 43 | Proto-Oncogene Proteins |
| 43 | Imidazoles |
| 43 | Gene Expression Regulation, Bacterial |
| 43 | Fluorescent Dyes |
| 43 | Extracellular Signal-Regulated MAP Kinases |
| 43 | Diet, High-Fat |
| 42 | Surface Properties |
| 42 | Species Specificity |
| 42 | Proteomics |
| 42 | Permeability |
| 42 | Nitric Oxide Synthase |
| 42 | Molecular Docking Simulation |
| 42 | Liposomes |
| 42 | Insulin-Like Growth Factor I |
| 42 | Drug Combinations |
| 42 | DNA, Bacterial |
| 42 | Curcumin |
| 42 | Chemical and Drug Induced Liver Injury |
| 42 | Cell Nucleus |
| 42 | Adenocarcinoma |
| 41 | RAW 264.7 Cells |
| 41 | Protein Processing, Post-Translational |
| 41 | Neovascularization, Physiologic |
| 41 | Microscopy, Fluorescence |
| 41 | Lipid Metabolism |
| 41 | Infant, Newborn |
| 41 | Half-Life |
| 41 | Genetic Therapy |
| 41 | Dopamine |
| 41 | Dermatologic Agents |
| 41 | Colonic Neoplasms |
| 41 | Cohort Studies |
| 41 | Cerebral Cortex |
| 41 | Cell Transformation, Neoplastic |
| 41 | CD4-Positive T-Lymphocytes |
| 41 | Atherosclerosis |
| 41 | Antibodies |
| 41 | Adjuvants, Immunologic |
| 40 | Ultraviolet Rays |
| 40 | Sulfonamides |
| 40 | Receptors, G-Protein-Coupled |
| 40 | MicroRNAs |
| 40 | Interleukins |
| 40 | Injections, Intravenous |
| 40 | Inhibitory Concentration 50 |
| 40 | Chemokines |
| 40 | Bone and Bones |
| 40 | Biomarkers, Tumor |
| 40 | Bacterial Infections |
| 39 | Stilbenes |
| 39 | Sequence Homology, Amino Acid |
| 39 | Receptors, Cell Surface |
| 39 | Protease Inhibitors |
| 39 | Osteoblasts |
| 39 | Genes, Reporter |
| 39 | Fusarium |
| 39 | Electrophoresis, Polyacrylamide Gel |
| 39 | Drug Compounding |
| 39 | Anti-Obesity Agents |
| 39 | Angiotensin-Converting Enzyme Inhibitors |
| 38 | Sequence Alignment |
| 38 | Resveratrol |
| 38 | Paclitaxel |
| 38 | PPAR gamma |
| 38 | Osteoclasts |
| 38 | Microscopy, Confocal |
| 38 | MCF-7 Cells |
| 38 | Islets of Langerhans |
| 38 | Injections, Intraperitoneal |
| 38 | Immunotherapy |
| 38 | Eating |
| 38 | Dipeptides |
| 38 | Cross-Sectional Studies |
| 38 | Colorectal Neoplasms |
| 38 | Colon |
| 38 | Autophagy |
| 37 | Virulence |
| 37 | Tumor Burden |
| 37 | Transforming Growth Factor beta1 |
| 37 | Serotonin |
| 37 | Sensitivity and Specificity |
| 37 | Radiation-Protective Agents |
| 37 | Potassium |
| 37 | Phenols |
| 37 | Osteogenesis |
| 37 | Organ Size |
| 37 | Nuclear Proteins |
| 37 | Leukocytes |
| 37 | Leptin |
| 37 | JNK Mitogen-Activated Protein Kinases |
| 37 | Incidence |
| 37 | Hypothalamus |
| 37 | Genes, Bacterial |
| 37 | Drug Liberation |
| 37 | Depsipeptides |
| 37 | Coloring Agents |
| 37 | Catalase |
| 37 | Bradykinin |
| 36 | Sirolimus |
| 36 | RANK Ligand |
| 36 | Plants, Medicinal |
| 36 | Pancreatic Neoplasms |
